ADO: Covid-19 for USA & EU, page-439

so what we know as fact

we have developed a  proof of concept antigen COVID19/ FluA&B test

from the quarterly have produced 200 rapid test cassettes and have acquired commercially available antibody pairs, for the purpose of further increasing sensitivity of the test.

we already have our test partners in Axxin (for the reader) and Merck (300nm Europium particles)

instead of using this sp rise to pump out another c/r, we have obtained underwriting of our Dec options for $3.76m and in doing so secure financial security beyond 2021

now the speculation from Derek's interviews.

our test is sensitive enough to open up communities and kick start economies.as well as "of what looks to be an unmatched contribution to the COVID-19 point-of-care diagnostics space."

Derek seems to be quite confident of the optimisation we have achieved!!! also from the last press release "we are exploring opportunities for collaboration with device manufacturers to enable production and commercialisation". also we are looking to conduct clinical evaluations in Aust and or overseas in the near term.



we may get an update in the coming 4G, but I suspect our next ann concerning our COVID test to be a big one. no fluff Ann's coming from management these days. GLTAH....